Implementing biosimilars: a case study on pharmacovigilance best practice

Listen to Glenn Myers and Marta Trojniak as they discuss the added importance of pharmacovigilance during treatment with biosimilars and why it helps to identify unknown adverse drug reactions, and the risk elements that may lead to the progression of adverse drug reactions.


This webinar aims to educate learners on the various aspects of pharmacovigilance requirements and the reasons behind the reporting. Through monitoring of all aspects of biosimilar production – from storage and transport, through to delivery device and individual monitoring – patients may feel more confident, comfortable and have better adherence to treatment.

This 30-minute webinar features insights from expert faculty from across the globe as well as audience questions being answered.

Target audience

This educational activity is designed for hospital-based pharmacists and all other healthcare professionals involved in the management of patients with cancer.

Learning objectives

After watching this webinar, viewers will be able to:

  • Identify and assess key areas where post-marketing monitoring of biosimilars may provide important information on clinical safety and efficacy of biosimilars
  • Implement effective strategies for ensuring comprehensive monitoring and reporting of events that may impact efficacy and safety of biosimilars
  • Adopt measures to ensure the quality and completeness of the data for individual case safety monitoring and show how it can improve safety and clinical uptake of biosimilars
Glenn Myers

Glenn Myers

Clinical Pharmacist
Dr. Sheldon H Rubin Oncology Clinic, Moncton, New Brunswick, Canada

Marta Trojniak

Marta Trojniak

Assistant Director
Paediatric Hospital, Trieste, Italy